

Supplementary Table 6. Diagnostic performance of each US RSS for indeterminate nodules (accuracy)

US RSS	Accuracy (95% CrI)	
	Intermediate to high risk as positive	High risk as positive
ACR	0.53 (0.51–0.55)	0.76 (0.74–0.77)
ATA	0.64 (0.62–0.66)	0.79 (0.77–0.80)
EU	0.60 (0.56–0.63)	0.70 (0.68–0.73)
K	0.64 (0.62–0.66)	0.79 (0.77–0.80)
Kwak et al.	0.50 (0.41–0.59)	0.69 (0.67–0.71)
Overall	0.58 (0.54–0.62)	0.75 (0.73–0.76)

US RSS, ultrasound risk stratification systems; CrI, credible interval; ACR, American College of Radiology; ATA, American Thyroid Association; EU, European Thyroid Association; K, Korean Society of Thyroid Radiology.

References

- Ahmedi S, Herbst R, Oyekunle T, Jiang X, Strickland K, Roman S, et al. Using the ATA and ACR TI-RADS sonographic classifications as adjunctive predictors of malignancy for indeterminate thyroid nodules. *Endocr Pract* 2019;25:908-917.
- Al Dawish M, Alwin Robert A, Al Shehri K, Hawsawi S, Mujammami M, Al Basha IA, et al. Risk Stratification of Thyroid Nodules with Bethesda III Category: The Experience of a Territorial Healthcare Hospital. *Cureus* 2020;12:e8202.
- Barbosa TLM, Junior COM, Graf H, Cavalvanti T, Trippia MA, da Silveira Ugino RT, et al. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology. *BMC Endocr Disord* 2019;19:112.
- Baser H, Cakir B, Topaloglu O, Alkan A, Polat SB, Dogan HT, et al. Diagnostic accuracy of Thyroid Imaging Reporting and Data System in the prediction of malignancy in nodules with atypia and follicular lesion of undetermined significance cytologies. *Clin Endocrinol (Oxf)* 2017;86:584-590.
- Capezzone M, Cantara S, Di Santo A, Sagnella A, Pilli T, Brilli L, et al. The combination of sonographic features and the seven-gene panel may be useful in the management of thyroid nodules with indeterminate cytology. *Front Endocrinol (Lausanne)* 2021;12:613727.
- Celletti I, Fresilli D, De Vito C, Bononi M, Cardaccio S, Cozzolino A, et al. TIRADS, SRE and SWE in INDETERMINATE thyroid nodule characterization: which has better diagnostic performance? *Radiol Med* 2021;126:1189-1200.
- Chaigneau E, Russ G, Royer B, Bigorgne C, Bienvenu-Perrard M, Rouxel A, et al. TIRADS score is of limited clinical value for risk stratification of indeterminate cytological results. *Eur J Endocrinol* 2018;179:13-20.
- Chirayath SR, Pavithran PV, Abraham N, Nair V, Bhavani N, Kumar H, et al. Prospective study of Bethesda categories III and IV thyroid nodules: outcomes and predictive value of BRAF(V600E) mutation. *Indian J Endocrinol Metab* 2019;23:278-281.
- He YP, Xu HX, Zhao CK, Sun LP, Li XL, Yue WW, et al. Cytologically indeterminate thyroid nodules: increased diagnostic performance with combination of US TI-RADS and a new scoring system. *Sci Rep* 2017;7:6906.
- Hong HS, Lee JY. Diagnostic performance of ultrasound patterns by K-TIRADS and 2015 ATA guidelines in risk stratification of thyroid nodules and follicular lesions of undetermined significance. *AJR Am J Roentgenol* 2019;213:444-450.
- Hong MJ, Na DG, Baek JH, Sung JY, Kim JH. Cytology-ultrasonography risk-stratification scoring system based on fine-needle aspiration cytology and the Korean-Thyroid Imaging Reporting and Data System. *Thyroid* 2017;27:953-959.
- Slowinska-Klencka D, Wysocka-Konieczna K, Klencki M, Popowicz B. Diagnostic value of six thyroid imaging reporting and data systems (TIRADS) in cytologically equivocal thyroid nodules. *J Clin Med* 2020;9:2281.
- Koh J, Kim EK, Kwak JY, Yoon JH, Moon HJ. Repeat fine-needle aspiration can be performed at 6 months or more after initial atypia of undetermined significance or follicular lesion of undetermined significance results for thyroid nodules 10 mm or larger. *Eur Radiol* 2016;26:4442-4448.
- Maia FF, Matos PS, Pavin EJ, Zantut-Wittmann DE. Thyroid imaging reporting and data system score combined with Bethesda system for malignancy risk stratification in thyroid nodules with indeterminate results on cytology. *Clin Endocrinol (Oxf)* 2015;82:439-444.
- Mao F, Xu HX, Zhao CK, Bo XW, Li XL, Li DD, et al. Thyroid imaging reporting and data system in assessment of cytological Bethesda Category III thyroid nodules. *Clin Hemorheol Microcirc* 2017;65:163-173.
- Marina M, Zatelli MC, Goldoni M, Del Rio P, Corcione L, Martorana D, et al. Combination of ultrasound and molecular testing in malignancy risk estimate of Bethesda category IV thyroid nodules: results from a single-institution prospective study. *J Endocrinol Invest* 2021;44:2635-2643.
- Mehta S, Kannan S. Approaching indeterminate thyroid nodules in the absence of molecular markers: "The BETH-TR score". *Indian J Endocrinol Metab* 2020;24:170-175.